{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-030205","form_type":"8-K","ticker":"EXOZ","cik":"0002010788","company_name":"EXOZYMES INC.","filed_at":"2026-06-25T23:36:23+00:00","discovered_at":"2026-06-26T10:05:00.291241+00:00","generated_at":"2026-06-26T10:05:26.876722+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"eXoZymes receives $2M NIH Phase IIB SBIR grant for cannabinoid analog drug discovery","bullets":["NIH NIGMS Phase IIB SBIR grant of $2,028,518 to support development of rare cannabinoids and engineered analogs.","Work on two-year grant begins July 1, 2026; total non-dilutive funding now ~$19.7M.","Grant adds a second biosolution to eXoZymes' pipeline after NCT, targeting pharmaceutical partnerships.","U.S. minor cannabinoids market forecast to grow from $11.5B (2023) to $33.3B (2030) at ~15% CAGR."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-030205","json":"https://secwatch.observer/filing/0001493152-26-030205.json","markdown":"https://secwatch.observer/filing/0001493152-26-030205.md","text":"https://secwatch.observer/filing/0001493152-26-030205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/0001493152-26-030205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2010788/000149315226030205/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T10:05:26.876722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}